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Background: Polyneuropathy presumably lowers quality of life (QoL). However, there is a lack of systematic studies
that assess QoL changes and biomarkers of polyneuropathy as determinants of QoL. We aimed to investigate the
relationship between every specific aspect of QoL and the clinical parameters used to assess the impairment of
motor, sensory (large and small fibers), and autonomic nerves in polyneuropathy.
Methods: Polyneuropathy patients were recruited from September 2013 to March 2014; QoL was assessed using
(1) the WHO Quality of Life-BREF (WHOQoL), (2) the European Quality of Life-5 Dimensions, and (3) the Brief Pain
Inventory Short Form. Neuropathy examinations included nerve conduction studies, autonomic function tests,
quantitative sensory testing (QST), and intraepidermal nerve fiber (IENF) density assessment of skin biopsies.
Results: There were 61 polyneuropathy patients (male/female = 38/23, mean age 58.14 ± 12.95 years). Patients had a
lower QoL than age-and gender-matched controls in the physical and psychological domains of the WHOQoL. Among
the biomarkers for different nerve fiber categories, only the small fiber neuropathy assessments were significantly related
to all domains of the WHOQoL. In contrast, the parameters of the large fiber neuropathy were independent of QoL.
Patients with abnormal temperature thresholds and a lower IENF density had lower WHOQoL scores compared to
patients with normal thresholds and IENF densities. Warm threshold of the foot in QST was linearly correlated with all
domains of the WHOQoL.
Conclusions: QoL scores were reduced in polyneuropathy, and biomarkers of small fiber neuropathy, i.e., warm threshold
and IENF density were discriminating predictors of QoL.
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Polyneuropathy resulting from different etiologies, such
as diabetes, autoimmune diseases, and hereditary neur-
opathy, causes various impairments and presumably in-
fluences quality of life (QoL) [1, 2]. The measurements
of QoL provide quantitative and functional assessments
of these relations [3]. The extensive involvement of
nerve fibers with different types of polyneuropathy usu-
ally leads to impaired physical activities and symptoms
interfering daily living, such as reduced muscle strength
and neuropathic pain [4].
Studies investigating the QoL in polyneuropathy co-
horts, however, have been limited and are often inconclu-
sive [3, 4]. According to pathology patterns, physiological* Correspondence: lukaslee@nhri.org.tw; ccchao@ntu.edu.tw
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be categorized into large and small fiber types. Symp-
toms of large fiber neuropathy include weakness of
limbs and a loss of proprioception resulting in sen-
sory ataxia, which are evaluated using conventional
nerve conduction studies (NCS). Symptoms of small
fiber neuropathy include reductions in temperature
sensations and autonomic functions with frequent
neuralgia [5]. Traditionally, the assessment and diag-
nosis of small fiber neuropathy has primarily
depended on the subjective description of symptoms
[6]. To facilitate accurate diagnosis, several groups,
including ours, have established quantifiable parame-
ters for small fiber neuropathy, i.e., temperature
thresholds determined by quantitative sensory testing
(QST) and intraepidermal nerve fiber (IENF) density
of skin biopsies [7, 8].istributed under the terms of the Creative Commons Attribution 4.0
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creased mortality in diabetic patients [9]. Neurological
impairments were previously assessed using mea-
sures of health-related QoL (HRQoL) [10], which
provides evaluations on health status, i.e., disease
impacts on health-related domains of QoL. A previ-
ous comprehensive review linked HRQoL to clinical
variables, formulating a conceptual model which in-
cluded five domains of patient reported outcomes:
biological and physiological factors, symptoms, func-
tioning, general health perceptions, and overall QoL
[11]. Previous studies have mainly used the HRQoL
measure SF-36 or disease-specific measures of
HRQoL, such as PN-QoL-97 or NeuroQoL [12], and
only a few studies have investigated global links to
QoL [13]. Thus, the influences of polyneuropathy on
the global QoL have not yet been systematically ex-
amined. In this study, we used the WHO Quality of
Life-BREF (WHOQoL), a measure of global QoL to
evaluate the associations of polyneuropathy with
QoL. The aim of our study was to investigate the re-
lationship between every specific aspect of global
QoL and biomarkers of polyneuropathy, including
large and small fiber nerves, i.e., parameters of nerve




Patients with polyneuropathy were recruited from
the Department of Neurology, National Taiwan Uni-
versity Hospital, Taipei, Taiwan from January 2013 to
March 2014.
The recruitment was consecutive case series where
board-certificated neurologist examined all the pa-
tients with standard approach. Polyneuropathy was
diagnosed according to (1) a symmetric and length-
dependent symptoms and signs in the motor or sen-
sory systems [14], and (2) abnormality in nerve con-
duction study or skin biopsy of the leg suggestive of
neuropathy. The neurological examinations followed
routine procedures and included detailed assess-
ments of muscle strength and the sensations to heat,
cold, pinprick, and vibratory stimuli. Laboratory ex-
aminations included the NCS (Additional file 1),
QST, autonomic function tests (Additional file 1),
and skin biopsy. The underlying etiologies of poly-
neuropathy were evaluated using a battery of tests
for diabetes, endocrine, autoimmune, and genetic
neuropathies as previously described [14]. QoL was
surveyed using the following questionnaires: (1) the
WHO Quality of Life-BREF (WHOQoL), (2) the
European Quality of Life-5 Dimensions (EQ-5D), and
(3) the Brief Pain Inventory Short Form (BPI-SF).Standard protocol approvals, registrations, and patient
consents
This study was conducted following the World Med-
ical Association’s Declaration of Helsinki. The proto-
cols were approved by the Institutional Review Board
of National Taiwan University Hospital, Taipei, Taiwan
(IRB No. 201306078RINC). Patients signed an in-
formed consent document before participation. Proce-
dures of the tests (nerve conduction studies,
quantitative sensory testing, autonomic function tests,
and skin biopsy for quantitation of epidermal inner-
vaion) followed established protocols and age-and
gender-matched control subjects were retrieved from
a previously described database [15]. All these were
detailed in the following and in the Supplementary
Methods.
World health organization quality of life instrument
We used the WHOQoL questionnaires to assess the
global QoL in 4 domains, physical, psychological, so-
cial, and environment [13, 16]. To evaluate the glo-
bal impacts of polyneuropathy, the WHOQoL scores
of our patients were compared with scores from
gender-and age-matched healthy Taiwanese control
subjects (Additional file 1).
European Quality of Life-5 Dimensions (EQ-5D)
It is a descriptive system to form an index score
(EQ index) covering 5 dimensions of HRQoL, mobil-
ity, self-care, usual activity, pain/discomfort, anxiety/
depression, with a 3-point scale (1 point for ‘no
problem’, 2 point for ‘some problem’, and 3 point for
‘extreme problem’) in each dimension [17, 18]. In
addition, the EQ-5D also consists of a visual
analogue scale (EQ VAS) that ranges from 0 (worst
imaginable health state) to 100 (best imaginable
health state), which records the respondent’s self-
rated evaluation of HRQoL. The scores and index of
our patients were compared with those from gender-
and age-matched healthy Taiwanese control subjects
(Additional file 1).
Brief pain inventory short form
The Brief Pain Inventory short form (BPI-SF) Taiwan
version consists of numerical scales (0 ~ 10) for 3 com-
ponents: (1) pain severity score ‘within 1 week’ (2), pain
severity ‘right now’, and (3) pain interference score (the
average score from 7 items that represent interference
with daily functions, mood, sleep, and enjoyment of life)
[19] (Additional file 1).
Quantitative sensory testing
Quantitative sensory testing (QST) was performed using
a Thermal Sensory Analyzer (Medoc Advanced Medical
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thresholds for warm and cold sensations using a previ-
ously established standard procedure [20]. Thermal
thresholds were expressed as a warm threshold (WT)
and cold threshold (CT), and were measured at the the-
nar eminence and index of the hand and at the dorsum
and great toe of the foot. Cut-off values were designated
as the 95th percentile value (for warm threshold) and the
5th percentile value (for cold threshold) according to
our normative database [14]. In this study, the overall
QST results were classified as abnormal if at least 1
temperature threshold was beyond the cut-off value
(Additional file 1).Table 1 Clinical profiles of patients with polyneuropathy
Features
Men/Women
Age (Mean ± SD)








Impaired vibration sensation at ankles
Small-fiber sensory impairment
Impaired pinprick sensation
Burning or tingling sensation












a:Muscle strength: according to Medical Research Council (MRC) grade
b:Proximal muscle of upper limbs included abduction muscle of the shoulder. Dista
and grasp of the hand
c:Proximal muscle of lower limbs included hip flexion muscle. Distal muscles of low
d:Electric shock–like or cold-like pain
e:Chronic inflammatory demyelinating polyneuropathy (5), Sjögren syndrome (2), va
neuropathy (1)
f:Chemotherapy induced neuropathy (3): docetaxel (2), cisplatin (1) and metronidaz
g:Charcot-Marie-Tooth disease (3), familial amyloid polyneuropathy (7)Skin biopsy and quantitation of IENF density
We conducted skin biopsies to provide pathologic evi-
dence of small fiber neuropathy. Following our pub-
lished procedures, a skin biopsy was performed on the
distal leg after an informed consent document was
signed [21–23]. Sections of skin biopsies were immuno-
stained and quantified using a previously described
method [23] (Additional file 1).
Study design and statistical analysis
For each examined parameter, patients were classified
into two groups, normal and abnormal. The scores for




Proximal: 4.82 ± 0.59 / Distal: 4.68 ± 0.58 b












4 ( 6.6 %)
10 (16.4 %)
26 (42.6 %)
l muscles of upper limbs included flexion and extension muscles of the wrist
er limbs included dorsiflexion and plantar flexion muscles of the ankle
sculitic neuropathy (2), Guillain-Barré syndrome (1), IgM paraproteinemic
ole induced neuropathy (1)
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The parametric t-test or non-parametric Wilcoxon rank-
sum test were used depending on whether the data
followed a Gaussian distribution or not. Univariate and
multivariate linear regression models were used to ex-
plore the relationships between each domain of QoL
and examination parameter. A P<0.05 was considered
statistically significant. SAS 9.3 (SAS Institute Inc, Cary,
NC) was used for statistical analyses.
Results
Demographic data, clinical presentations, and QoL
measures of polyneuropathy
There were 61 polyneuropathy patients (male/female =
38/23) with a mean age of 58.14 ± 12.95 years and a
mean disease duration of 4.34 ± 3.26 years. The under-
lying etiologies consisted of diabetes, immune-related,
drug-induced, inherited, and idiopathic types. Neuro-
logical examinations assessed the functions of motor sys-
tem (muscle strength on a MRC grade), sensory and
autonomic system. Among small-fiber sensory impair-
ments, proportion of impaired pinprick sensation, burn-
ing or tingling sensation and other small fiber
characteristics (electric shock–like or cold-like pain) was
80.3 %, 77.0 % and 8.2 % respectively (Table 1).
To evaluate the global relations of polyneuropathy, we
surveyed different dimensions of QoL and compared
these results with age-and gender-matched healthy indi-
viduals. Among the 4 domains of the WHOQoL, poly-
neuropathy patients had significantly lower scores in the
physical domain (48.9 ± 10.8 vs. 68.1 ± 14.8, p < 0.0001)
and psychological domain (51.8 ± 13.2 vs. 60.6 ± 14.2,
p<0.0001). Among EQ-5D, polyneuropathy patients hadTable 2 Comparison of WHOQoL: between polyneuropathy patient
Polyneuropathy patients
N Score (Mean ± SD)
WHOQoL
Domain 1 (Physical) 61 48.9 ± 10.8
Domain 2 (Psychological) 61 51.8 ± 13.2
Domain 3 (Social) 61 64.7 ± 14.4
Domain 4 (Environment) 61 64.3 ± 14.1
EQ-5D
Mobility 61 1.56 ± 0.50
Self-care 61 1.26 ± 0.48
Usual activity 61 1.38 ± 0.49
Pain / discomfort 61 1.95 ± 0.46
Anxiety / depression 61 1.30 ± 0.56
Index 61 0.51 ± 0.26
VAS 61 63.67 ± 16.23
Abbreviation: WHOQoL WHO quality of life-BREF, EQ-5D European Quality of Life-5 Dsignificantly lower scores in all dimensions, index and
VAS (Table 2).
Small fiber function: sensory system
To investigate the association between small-diameter
sensory nerves and QoL, we used temperature thresh-
olds in QST and the IENF density of a skin biopsy as
biomarkers of small fiber sensory neuropathy.
In the QST, the abnormal rates for each functional
examination compared with age-stratified norms were
54.7 % for the warm threshold of the foot (WT-foot),
33.4 % for the warm threshold of the hand (WT-hand),
15.1 % for the cold threshold of the foot (CT-foot), and
20.7 % for the cold threshold of the hand (CT-hand).
Among these temperature thresholds, the warm thresh-
old of the foot had the highest abnormal rate. For the
IENF density analysis, the overall abnormal rate was
72.7 %, with a reduced IENF density in 80.0 % of the pa-
tients age <60 years and 66.7 % of the patients age >60
years.
There were significant differences in all domains of
the WHOQoL between patients with abnormal
temperature thresholds and those with normal QST
results (Fig. 1). The most significant differences, de-
termined by statistical p values, were found in the
physical domain (p = 0.014) and psychological domain
(p = 0.007) (Additional file 1: Table S1).
The quantitative analysis of skin biopsies revealed that
patients having a reduced IENF density, compared with
patients having a normal IENF density, reported signifi-
cantly lower scores in all of the WHOQoL domains
(physical, psychological, social, and environment), in
both of the EQ-5D categories (index and VAS), ands and gender- and age-matched healthy subjects
Matched healthy subjects P value (t-test)
N Score (Mean ± SD)
61 68.2 ± 12.5 <.0001
61 62.0 ± 13.8 <.0001
61 63.0 ± 12.4 0.4928
61 62.0 ± 14.3 0.3769
61 1.02 ± 0.13 <.0001
61 1.03 ± 0.26 <.0001
61 1.08 ± 0.28 <.0001
61 1.25 ± 0.43 <.0001
61 1.13 ± 0.34 0.089
61 0.88 ± 0.20 <.0001
61 73.56 ± 13.46 <.0001
imensions
Fig. 1 Small fiber impairment and quality of life (QoL) measurements. Box plot of small fiber sensory examination with QoL measures: quantitative
sensory testing (QST in a and b) and skin biopsy (c and d) in WHOQoL (a and c) and EQ-5D (b and d). Patients were classified into two groups: normal
(N) vs. abnormal (Ab) and each domain of QoL was analyzed accordingly. All domains of WHOQoL revealed significant association with QST results.
Skin biopsy examination was related to all domains of WHOQoL and EQ-5D. (The bottom and top of the box are the first and third quartiles, *
P<0.05,**P < 0.01,)
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(‘pain during the previous 1 week’ and ‘interference di-
mension’) (Fig. 1 and Additional file 1: Table S1).
When the QST and skin biopsy results were combined
as criteria for small fiber impairment (i.e., at least one ab-
normal temperature threshold or reduced IENF density),patients with small fiber impairment had significantly
lower scores in (1) all domains of the WHOQoL, (2) the
VAS category of the ED-5D, and (3) the interference di-
mension of the BPI-SF (Table 3).
In the facet-level analysis of WHOQoL, Pain and dis-
comfort (F1), Mobility (F9) and Activities of daily living
Table 3 Comparison of patients’ quality of life (Mean ± SD) between normal and abnormal groups
QST IENFD
Normal Abnormal P Normal Abnormal P
WHOQoL
Physical domain 14.0 ± 2.0 11.9 ± 2.7 0.014 15.0 ± 2.0 11.5 ± 2.5 0.0005
Psychological domain 14.2 ± 2.2 11.9 ± 2.8 0.007 14.8 ± 2.3 12.1 ± 2.7 0.006
Social domain 15.6 ± 1.7 14.2 ± 1.8 0.006 15.1 ± 1.9 14.3 ± 2.4 0.048
Environment domain 15.2 ± 1.4 13.8 ± 2.2 0.030 15.5 ± 1.6 13.9 ± 2.3 0.011
EQ-5D
Index 0.72 ± 0.09 0.68 ± 0.14 0.063 0.75 ± 0.04 0.68 ± 0.15 0.008
VAS 65 ± 20 62 ± 15 0.288 76 ± 13 57 ± 15 0.002
BPI-SF
1 week 4.32 ± 1.67 5.03 ± 1.58 0.148 3.50 ± 1.57 4.78 ± 1.56 0.033
Now 3.91 ± 2.00 5.06 ± 1.88 0.100 3.75 ± 1.66 4.56 ± 2.26 0.284
Interference 2.44 ± 1.86 4.36 ± 2.02 0.005 1.89 ± 1.64 4.21 ± 2.28 0.007
WHOQoL domain scores range from 4 to 20. EQ-5D Index scores range from 0 to 1, and VAS scores range from 0 to 1000. BPI-SF scores ranged from 0 (not pain-
ful) to 10 (most painful)
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abnormal QSTand IENF; these served as major contributing
factors to QoL reduction (Additional file 1: Table S4).
Univariate linear regression analyses showed the phys-
ical domain of the WHOQoL correlated with 4 inde-
pendent biomarkers of the QST (WT-hand, WT-foot,
CT-hand, and CT-foot) (Additional file 1: Table S2).
Multivariate linear regression was applied to investigate
which QST parameters made major contribution to the
4 domains of the WHOQoL. The warm threshold at the
foot was the only significant determinant for the all do-
mains in the WHOQoL (Table 4).
We then examined the relation of the warm threshold
of the foot and IENF density with the WHOQoL and
pain characters using univariate linear regression ana-
lysis. The warm threshold at the foot demonstrated a
linear correlation with the WHOQoL (physical, psycho-
logical and social domains) and BPI-SF (pain severity
and pain interference dimensions). In contrast, only the
IENF density demonstrated a linear association with the
pain severity dimension (‘within 1 week’ and ‘right now’,
β = -0.3, p = 0.003 and β = -0.31, p = 0.016, respectively)
of the BPI-SF (Additional file 1: Table S3).
Small fiber function: autonomic system
The abnormal rate of SSR and RRIV were 51.0% and
40.8.%, and in total 36.7 % (the number of abnormal SSR
and RRIV) of the patients had autonomic dysfunction.
In similar analyses for the RRIV and SSR examinations,
only the abnormal RRIV demonstrated a significant as-
sociation with a lower EQ5D index (p = 0.024) and a
higher pain severity dimension (in the dimensions of
within 1 week and right now) of the BPI-SF (p = 0.042
and p = 0.037, respectively) (Additional file 1: Table S1).Large fiber system
The abnormal rate of nerve conduction study was
59.6 %. For large fiber physiology, the parameters of
the NCS, including motor nerves and sensory nerves,
were analyzed according to their relationship with
every aspects of QoL. Only patients with a lower
SAP amplitude had a higher pain intensity in the
BPI-SF than patients with a normal SAP amplitude
(p = 0.038, Additional file 1: Table S1).
Discussion
This study reports a significant reduction in the QoL
with polyneuropathy according to global QoL assess-
ment results, especially in the physical and psychological
domains of the WHOQoL. Since weakness might be a
confounding factor of QoL, we focused on the compari-
son of sensory parameters between large and small fiber
impairment. Furthermore, the deterioration of QoL was
correlated with biomarkers of small fiber neuropathy,
i.e., thermal thresholds and IENF density. Presumably,
pain resulting from neuropathy influences QoL, as
shown in disease-specific instruments of the Norfolk
QoL-DN [24–26]. A recent cohort study of elderly dia-
betic patients documented that some clinical parame-
ters, including diabetes-related complications, smoking
status, and Body-Mass-Index, predicted physical compo-
nent scores of HRQoL [27]. There was, however, a lack
of quantifiable and objective parameters that could dem-
onstrate the relationships between impairment of small
fiber thermonociceptive nerves and global QoL. To ad-
dress this issue in our study, we used thermal thresholds
and IENF density as biomarkers of small fiber impair-
ment along with the autonomic function tests and NCS
as biomarkers of autonomic and large fiber impairments,
Table 4 Multivariate linear regression analysis: relationship of temperature thresholds (warm threshold, WT, and cold threshold, CT) of quantitative sensory testing with each
domain scores of WHOQoL
Domains WT–hand WT–foot CT–hand CT–foot Age Gender
Β SE P β SE P β SE P β SE P β SE P β SE P
Physical 0.14 0.087336 0.117 0.359058 0.093182 0.000 –0.00 0.07 0.989 –0.04 0.060085 0.5176839 0.100208 0.024192 0.000 0.31 0.589971 0.602164
Psychological domain 0.11 0.111826 0.348527 0.351689 0.119311 0.005157 –0.08 0.083298 0.319 –0.04 0.076934 0.560088 0.090342 0.030976 0.005605 –0.08 0.755407 0.919013
Social –0.02 0.081104 0.782848 0.279292 0.086533 0.002391 –0.04 0.060414 0.491 –0.02 0.055798 0.696015 0.067288 0.022466 0.004538 –0.07 0.547875 0.892668
Environment 0.07 0.088311 0.449768 0.202349 0.094222 0.037425 –0.04 0.065781 0.538 –0.04 0.060756 0.493875 0.059274 0.024462 0.020671 0.48 0.596555 0.426473
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IENF density were statistically significant in all do-
mains of the WHOQoL among all parameters of
polyneuropathy. Furthermore, the IENF density was
also a significant determinant for the EQ-5D and
BPI-SF. These 2 types of small fiber biomarkers had
different modes of influences on QoL scores. Ther-
mal threshold, especially the warm threshold on the
dorsum foot, was linearly correlated with the WHO-
QoL domain scores. In contrast, IENF density ap-
pears to exert a non-linear association (i.e., threshold
effect) on the WHOQoL and EQ-5D.
Previously QoL studies in polyneuropathy have mainly
focused on diseases with large fiber impairment, such as
Guillain-Barré syndrome (GBS), chronic inflammatory
demyelinating polyneuropathy (CIDP), and Charcot-
Marie-Tooth disease. Despite the documented reduction
in QoL, no relationships among the electrophysiological
measurements of the NCS, GBS disability score, and
QoL score in the GBS were revealed [28]. In a random-
ized trial of CIDP, there was no significant correlation
between the NCS parameters and QoL scores except for
some significant variables after intravenous immuno-
globulin treatment [29]. Rare reports of Charcot-Marie-
Tooth disease indicated that there are some correlations
between reduced NCS parameters (CMAP amplitude)
and the physical and social functions of QoL [30].
The association between small fiber impairment and
QoL have received less attention than the association
between large fibers and QoL [25], even though small
fiber neuropathy is prevalent in polyneuropathy of
common etiologies (i.e diabetes mellitus, chronic kid-
ney disease, drugs or toxin, and autoimmune) [1, 2].
Only one study specifically focused on small fiber
neuropathy (based on reduced IENF density, abnor-
mal thermal thresholds, and absence of large fiber im-
pairment) was found and showed that there is
reduced HRQoL in these patients [25]. These studies
raise intriguing issues, such as (1) the influence of
small fibers vs. large fibers on global QoL and (2)
specific biomarkers of polyneuropathy as determinants
of QoL. Given the complexity of polyneuropathy,
small fiber impairment and large fiber neuropathy fre-
quently coexist. It remains unclear, however, how
small fiber neuropathy affects QoL. In this study,
many aspects of QoL were highly correlated with
thermal threshold or IENF density but were inde-
pendent of the parameters of the NCS. These results
indicate that the parameters of small fiber neuropathy
are better predictors of QoL scores in polyneuropathy
than the parameters of large fiber neuropathy. Ther-
mal thresholds demonstrated linear correlations with
the WHOQoL, and the warm threshold of the foot
(WT-foot) was the most significant biomarker for thephysical, psychological, and social domains of the
WHOQoL. A previous study from our group re-
ported a linear correlation between the thermal
thresholds of the QST and the IENF density in a
skin biopsy, and the foot warm threshold demon-
strated the highest correlation with the IENF density
in patients with type 2 diabetes [14]. The present
study further demonstrates that the thermal thresh-
olds (especially the warm threshold) at the foot and
a skin biopsy not only reflect functional deficits and
pathological changes in small fiber neuropathy, but
they also predict a deterioration in QoL. These ob-
servations extend the clinical significance and appli-
cations of QST and a skin biopsy.
Despite the promising results of this study, several lim-
itations are recognized. The comparison group for
WHOQoL matched healthy subjects was retrieved from
historical data. This study is a cross-sectional study per-
formed at a single tertiary-care medical center and the
etiologies of polyneuropathy in our studies patients were
varied, which may limit the generalization of its findings
to primary clinics. On the other hand, the diverse dis-
ease etiologies included in this study means that these
observations might be applicable to polyneuropathy
caused by different etiologies. Larger databases are ne-
cessary to identify the precise contributing factors lead-
ing to a reduced QoL, and may lead to the design of
therapeutic approaches that improve treatment efficacy.
How will the QoL measures assessed in this study
benefit patient care? Our validation of QoL promotes its
use as a follow-up instrument in patients with small
fiber neuropathy. Physicians can monitor disease pro-
gression by repeated measurements of HRQOL in their
clinical practice. In addition, temporal changes of
HRQoL along with the lifetime course of the illness can
reflect patient’s functional state (i.e., physical, psycho-
logical and social domain) and utility [31], which are
major outcomes of medical care. Using EQ-5D or
WHOQoL-BREF instruments in clinical settings is
relatively easy and very feasible; it takes about 10 mi-
nutes to complete the whole set of questionnaires
based on our experiences. Our findings hint at the as-
sociation between clinical measures of diagnosis tools
(such as QST and the IENF density) at baseline and
HRQoL measured in a cross-sectional survey. Further
studies are needed to measure the longitudinal
changes of HRQoL along withdifferent treatment mo-
dalities to investigate whether HRQoL is a predictor
of long-term prognosis in patients, is a measure of
disease burden in terms of savings of expected life
years [32], or quality-adjusted life expectancy [33].
Expanding this study to estimate the lifetime health-
care expenditures [34] may facilitate the cost effect-
iveness analysis of multiple healthcare interventions.
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Our current study demonstrates biomarkers of small
fiber impairment, including temperature thresholds in
QST and the IENF density in a skin biopsy, were signifi-
cant determinants of QoL in polyneuropathy patients.
Furthermore, there was a linear correlation between the
warm threshold of the foot and the QoL scores in the
physical domain of the WHOQoL.Additional file
Additional file 1: Table S1. Comparison of abnormal and normal
patients’ quality of life (QoL). Table S2. Univariate linear regression
analysis: relationship of temperature thresholds (warm threshold, WT, and
cold threshold, CT) of quantitative sensory testing with quality of life
(QoL). Table S3. Univariate linear regression analysis of IENF density and
WT-foot with quality of life (QoL). Table S4. Facet-level comparison of
WHOQoL. (DOC 184 kb)
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